A Newly Published Network Meta-Analysis (NMA) Found TREMFYA® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies

SPRING HOUSE, Pa., Jan. 24, 2022 /PRNewswire/ — The Janssen Pharmaceutical Corporations of Johnson & Johnson at this time introduced a Community Meta-Evaluation (NMA) evaluating first-in-class interleukin (IL)-23 inhibitor TREMFYA^® (guselkumab) to all superior therapies^a authorised for energetic psoriatic arthritis (PsA) utilizing information from 33 Section 3 randomized medical trials (RCTs).¹ The NMA concluded TREMFYA ranked highest^b for pores and skin clearance based mostly on Psoriasis (PsO) Space Severity Index (PASI)^c 90 response amongst 23 therapy regimens (15 distinctive remedies together with IL-23 inhibitors like TREMFYA and risankizumab, subcutaneous [SC] tumor necrosis issue inhibitors [TNFi], and Janus kinase inhibitors [JAKi]).¹ When it comes to joint irritation enchancment, each TREMFYA dosing regimens (100 mg each 4 weeks [q4w] and each eight weeks [q8w])^d had been comparable^b to most different remedies for the modified van der Heijde-Sharp (vdH-S)^e rating, and TREMFYA was typically comparable^b to TNFi and most IL-17Ai for American Faculty of Rheumatology (ACR) 20 response.^1,f The evaluation additionally confirmed the established security profile of TREMFYA in energetic PsA.¹ The NMA is being offered on the Maui Dermatology 2022 Assembly going down January 24-28, 2022. TREMFYA is U.S. Meals and Drug Administration (FDA) authorised for administration as a 100 mg SC injection q8w, following two preliminary doses at weeks 0 and 4.^2,d

“This complete analytical strategy helps to supply a helpful comparative image of obtainable psoriatic arthritis medicines,” stated Philip J. Mease,^g M.D., Swedish Medical Middle/Windfall St. Joseph Well being and College of Washington in Seattle, Washington. “In my expertise, thorough NMAs resembling this one may also help equip physicians to debate therapy decisions and therapeutic outcomes with their sufferers in every day observe.”  

NMA is a structured, protocol-driven analytical course of extensively accepted and utilized by regulatory companies, well being know-how evaluation companies and medical guideline committees to comparatively consider therapy choices the place head-to-head information are restricted or unavailable.^3-5 NMA is essentially the most cited and essentially the most complete technique obtainable to match research not directly; nonetheless, NMAs can’t change and shouldn’t be thought of the identical as head-to-head medical trials. On this NMA, the timing of main endpoint evaluation assorted throughout RCTs, and placebo was used because the reference therapy all through excluding two head-to-head research.¹ Baseline threat adjustment was used to account for heterogeneity throughout research populations. The NMA builds on earlier analyses, together with a 2021 publication in Rheumatology, and now incorporates all latest medical information updates, together with the COSMOS research of TREMFYA in PsA sufferers who had an insufficient response to TNFi, in addition to information for 2 new comparators, the IL-23i risankizumab and the JAKi upadacitinib.^1,6,7 

NMA outcomes confirmed:¹

• Pores and skin Clearance: TREMFYA ranked first and second^b in PASI 90 response for q4w^d and q8w dosing, respectively.
• Joint Irritation Enchancment: TREMFYA was akin to SC TNFi and most IL-17Ai, as measured by ACR20 response. Whereas dosing frequency impacted modified vdH-S rating,^e each TREMFYA dosing regimens achieved enhancements that had been akin to most remedies and each doses of TREMFYA ranked extra extremely on vdH-S rating than risankizumab and upadacitinib.^b
• Low Numbers of Critical Antagonistic Occasions (SAEs): TREMFYA confirmed low charges of SAEs, with each dosing regimens rating favorably among the many 23 remedies for low charges of occasions. The variety of SAEs for TREMFYA had been per the established TREMFYA security profile.¹

“Psoriatic arthritis is a posh illness, and physicians should contemplate many elements when making therapy selections, together with the relative efficacy of therapies in treating each pores and skin and joints, in addition to established security,” stated Terence Rooney, M.D., Vice President, Rheumatology and Maternal-Fetal Immunology Illness Space Chief, Janssen Analysis & Growth, LLC. “NMAs are a complete, well-established strategy, and might present physicians with helpful info on obtainable therapies.”

TREMFYA was authorised within the U.S. for the therapy of grownup sufferers with reasonable to extreme plaque PsO in July 2017 and in July 2020 for adults with energetic PsA.² The PsA approval was based mostly on outcomes from DISCOVER-1 and DISCOVER-2, which confirmed TREMFYA achieved the research’ main endpoint of ACR20 response at 24 weeks.^8,9 A complete evaluation of DISCOVER-2 information was not too long ago printed in Arthritis & Rheumatology, representing the ultimate outcomes of the first-ever two-year medical trial with an open label extension investigating a selective IL-23 inhibitor remedy in energetic PsA.¹⁰

Janssen will current 5 further posters on the Maui Dermatology Assembly, together with the research design of APEX (NCT04882098),¹¹ investigating the impact of TREMFYA on radiographic development;^h the design of the SOLSTICE trial (NCT04936308),¹² which additional evaluates TREMFYA efficacy for PsA sufferers with intolerance or insufficient response to TNF remedy; proof of molecular and genetic distinctions between sufferers with axial PsA (axPsA) and ankylosing spondylitis and the numerous pharmacodynamic results of TREMFYA in axPsA sufferers; and real-world proof for PsA sufferers initiating TREMFYA therapy within the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry.

Editor’s Notice:

a. Superior therapies had been outlined as any focused or biologic therapies for the therapy of PsA together with: TNFi, JAKi, IL-17Ai, IL-12/23i, IL-23i, PDE4i, CTLA-4i, biologic biosimilar brokers, and placebo/no therapy.¹

b. Outcomes are summarized by rating remedies in line with findings derived from NMAs. Conclusions (i.e., comparable) are based mostly on an overlap of pairwise 95 p.c credible intervals.¹

c. PASI 90 is outlined as no less than 90 p.c enchancment from baseline within the PASI rating. The PASI rating grades the quantity of floor space on every physique area that’s coated by PsO plaques and the severity of plaques for his or her redness, thickness, and scaliness.¹³ PASI 90 was not a managed endpoint in DISCOVER-1 or -2.^8,9

d. TREMFYA q4w dosing will not be presently FDA-approved.²

e. The PsA-modified vdH-S rating combines erosion and joint house narrowing scores derived from radiographs of joints in physique areas impacted by PsA.¹⁴ TREMFYA will not be authorised within the U.S. for inhibition of structural injury.²

f. ACR20 response is outlined as each no less than 20 p.c enchancment from baseline within the variety of tender and variety of swollen joints, and a 20 p.c enchancment from baseline in three of the next 5 standards: affected person world evaluation, doctor world evaluation, practical skill measure, visible analog ache scale, and erythrocyte sedimentation price or C-reactive protein.¹⁵

g. Dr. Mease is a paid guide for Janssen. He has not been compensated for any media work.

h. Radiographic development is a key indicator of structural injury, which incorporates erosion and joint house narrowing. Radiographic development will not be within the FDA label for TREMFYA.²

Concerning the Community Meta-Evaluation¹
A scientific literature evaluate was performed to establish randomized managed trials as much as February 2021. A hand search recognized newer brokers as much as July 2021. These searches recognized 33 Section 3 RCTs finding out 15 focused therapies for PsA authorised or underneath evaluate by the U.S. FDA or the European Medicines Company in sufferers who had been TNFi-naïve, TNFi-experienced, had an insufficient response (IR), or combined populations for inclusion on this NMA, via July 2021. Bayesian NMAs had been carried out to match therapies on ACR20 response, PASI response, modified vdH-S rating and SAEs. Analyses used random results fashions wherever potential, and stuck results fashions when not. Wherever potential, analyses included meta-regression on baseline threat (placebo response) with the intention to cut back bias. Multinomial fashions had been used for ACR and PASI. A number of NMAs have in contrast the efficacy of remedies obtainable for PsA, however none of those analyses have included the newest Section 3 information for TREMFYA within the TNFi-IR inhabitants or the newest comparators risankizumab and upadacitinib.^16-19 The target of this research was to replace the prior NMAs to incorporate these new information to find out the relative pores and skin and joint efficacy and security for therapies obtainable for PsA via NMA.

This NMA adheres to all governing requirements and necessities as demanded by world well being know-how evaluation companies, journal evaluate committees and regulatory authorities. The NMA was funded by Janssen Analysis & Growth, LLC.

About COSMOS (NCT03796858)⁷
COSMOS was a Section 3b, multicenter, randomized, double-blind, placebo-controlled research to guage the protection and efficacy of TREMFYA in 285 sufferers with energetic PsA and IR to TNFi remedy. The first endpoint was ACR20 response at week 24. Contributors had been randomized (2:1) to obtain TREMFYA 100 mg at weeks 0, 4 and q8w thereafter, or placebo. The research included two durations: a 24-week double-blind, placebo-controlled interval for the first evaluation of the efficacy and security of TREMFYA in contrast with placebo and a 32-week active-treatment and security follow-up interval for added evaluation of the efficacy and security of TREMFYA. Via week 48, non-responder imputation (NRI) guidelines had been used for lacking information (after the applying of therapy failure guidelines [TFR]). Security was monitored all through the research to week 56.

About DISCOVER-1 (NCT03162796)⁸
DISCOVER-1 was a randomized, double-blind, multicenter Section 3 research evaluating the efficacy and security of TREMFYA administered by SC injection in individuals with energetic PsA, together with these beforehand handled with one or two TNF inhibitors. DISCOVER-1 evaluated 381 individuals who had been handled and adopted via roughly one 12 months. The first endpoint was response of ACR20 at week 24 and first endpoint information had been beforehand offered at scientific congresses and printed in The Lancet. Along with ACR20, a number of different medical outcomes had been assessed, together with ACR50/70, decision of soppy tissue irritation, enthesitis and dactylitis, enchancment in bodily operate, pores and skin clearance (IGA), and basic well being outcomes (36-Merchandise Brief-Type Well being Survey [SF-36] Bodily Element Abstract [PCS] and Psychological Element Abstract [MCS]).

The research consisted of a screening part of as much as six weeks, a blinded therapy part of 52 weeks that included a placebo-controlled interval from week 0 to week 24 and a blinded energetic therapy interval from week 24 to week 52. It additionally included a security follow-up part via week 60 (i.e., roughly 12 weeks from the final administration of research agent at week 48). Efficacy, security, pharmacokinetic, immunogenicity and biomarker evaluations had been carried out within the research on an outlined schedule.

About DISCOVER-2 (NCT03158285)⁹
DISCOVER-2 is a randomized, double-blind, multicenter Section 3 research evaluating the efficacy and security of TREMFYA administered by SC injection in biologic-naïve sufferers with energetic PsA. DISCOVER-2 evaluated 739 individuals who had been handled and adopted via roughly two years. The first endpoint was response of ACR20 at week 24 and first endpoint information had been beforehand offered at scientific congresses and printed in The Lancet. Along with ACR20, a number of different medical outcomes had been assessed, together with ACR50/70; decision of soppy tissue irritation, enthesitis and dactylitis; enchancment in bodily operate; pores and skin clearance (IGA); and basic well being outcomes (SF-36 PCS and MCS). DISCOVER-2 additionally assessed adjustments in structural injury as a key secondary endpoint (PsA-modified vdH-S rating).

The research consisted of a screening part of as much as six weeks, a blinded therapy part of roughly 100 weeks that included a placebo-controlled interval from week 0 to week 24 and a blinded energetic therapy interval from week 24 to week 100. It additionally included a security follow-up part via week 112 (i.e., roughly 12 weeks after the final administration of research agent at week 100). Scientific efficacy, radiographic efficacy, well being economics, security, pharmacokinetics, immunogenicity, biomarker, and pharmacogenomics evaluations had been carried out within the research on an outlined schedule.

About Psoriatic Arthritis (PsA)
PsA is a persistent, immune-mediated inflammatory illness characterised by peripheral joint irritation, enthesitis (ache the place the bone, tendon and ligament meet), dactylitis (extreme irritation of the fingers and toes), axial illness, and the pores and skin lesions related to plaque PsO.^20-22 As well as, in sufferers with PsA, comorbidities, resembling weight problems, cardiovascular illnesses, nervousness and despair are sometimes current.²³ Research present as much as 30 p.c of individuals with plaque PsO additionally develop PsA.²⁴ The illness causes ache, stiffness and swelling in and across the joints; it generally seems between the ages of 30 and 50, however can develop at any age.²⁴ Almost half of sufferers with PsA expertise reasonable fatigue and about 30 p.c endure from extreme fatigue as measured by the modified fatigue severity scale.²⁵ Though the precise reason for PsA is unknown, genes, the immune system and environmental elements are all believed to play a job in illness onset.²⁶

About TREMFYA^® (guselkumab)²
Developed by Janssen, TREMFYA is the primary authorised absolutely human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interplay with the IL-23 receptor. IL-23 is a vital driver of the pathogenesis of inflammatory illnesses resembling reasonable to extreme plaque PsO and energetic PsA.²⁷ TREMFYA is authorised within the U.S., Canada, Japan, and quite a lot of different international locations worldwide for the therapy of adults with reasonable to extreme plaque PsO who’re candidates for injections or tablets (systemic remedy) or phototherapy (therapy utilizing ultraviolet mild), and for the therapy of grownup sufferers with energetic PsA. Additionally it is authorised within the EU for the therapy of reasonable to extreme plaque PsO in adults who’re candidates for systemic remedy and for the therapy of energetic PsA in grownup sufferers who’ve had an insufficient response or who’ve been illiberal to a previous disease-modifying antirheumatic drug remedy. 

The Janssen Pharmaceutical Corporations of Johnson & Johnson keep unique worldwide advertising and marketing rights to TREMFYA^®.

IMPORTANT SAFETY INFORMATION

What’s crucial info I ought to find out about TREMFYA^®?
TREMFYA^® is a prescription drugs which will trigger critical uncomfortable side effects, together with:

Don’t take TREMFYA^® you probably have had a critical allergic response to guselkumab or any of the elements in TREMFYA^®.

Earlier than utilizing TREMFYA^®, inform your healthcare supplier about all your medical situations, together with in the event you:

• have any of the situations or signs listed within the part “What’s crucial info I ought to find out about TREMFYA^®?”
• have an an infection that doesn’t go away or that retains coming again.
• have TB or have been in shut contact with somebody with TB.
• have not too long ago obtained or are scheduled to obtain an immunization (vaccine). It’s best to keep away from receiving reside vaccines throughout therapy with TREMFYA^®.
• are pregnant or plan to turn into pregnant. It isn’t identified if TREMFYA^® can hurt your unborn child.
• are breastfeeding or plan to breastfeed. It isn’t identified if TREMFYA^® passes into your breast milk.

Inform your healthcare supplier about all of the medicines you’re taking, together with prescription and over-the-counter medicines, nutritional vitamins, and natural dietary supplements.

What are the potential uncomfortable side effects of TREMFYA^®?
TREMFYA^® might trigger critical uncomfortable side effects. See “What’s crucial info I ought to find out about TREMFYA^®?”

The commonest uncomfortable side effects of TREMFYA^® embrace: higher respiratory infections, headache, injection web site reactions, joint ache (arthralgia), diarrhea, abdomen flu (gastroenteritis), fungal pores and skin infections, herpes simplex infections, and bronchitis.

These aren’t all of the potential uncomfortable side effects of TREMFYA^®. Name your physician for medical recommendation about uncomfortable side effects.

Use TREMFYA^® precisely as your healthcare supplier tells you to make use of it.

Please learn the total Prescribing Information, together with Medication Guide for TREMFYA^®, and focus on any questions that you’ve together with your physician.

You’re inspired to report destructive uncomfortable side effects of pharmaceuticals to the FDA. Go to www.fda.gov/medwatch, or name 1-800-FDA-1088.

cp-82626v3

Concerning the Janssen Pharmaceutical Corporations of Johnson & Johnson

At Janssen, we’re making a future the place illness is a factor of the previous. We are the Pharmaceutical Corporations of Johnson & Johnson, working tirelessly to make that future a actuality for sufferers in all places by combating illness with science, enhancing entry with ingenuity, and therapeutic hopelessness with coronary heart. We give attention to areas of medication the place we will make the largest distinction: Cardiovascular & Metabolism, Immunology, Infectious Illnesses & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Be taught extra at www.janssen.com. Observe us at www.twitter.com/JanssenGlobal.

Janssen Analysis & Growth, LLC is part of the Janssen Pharmaceutical Corporations of Johnson & Johnson.

Cautions Regarding Ahead-Wanting Statements

This press launch accommodates “forward-looking statements” as outlined within the Non-public Securities Litigation Reform Act of 1995 relating to TREMFYA^® (guselkumab) product growth. The reader is cautioned to not depend on these forward-looking statements. These statements are based mostly on present expectations of future occasions. If underlying assumptions show inaccurate or identified or unknown dangers or uncertainties materialize, precise outcomes may range materially from the expectations and projections of Janssen Analysis & Growth, LLC, any of the opposite Janssen Pharmaceutical Corporations and/or Johnson & Johnson. Dangers and uncertainties embrace, however aren’t restricted to: challenges and uncertainties inherent in product analysis and growth, together with the uncertainty of medical success and of acquiring regulatory approvals; uncertainty of economic success; manufacturing difficulties and delays; competitors, together with technological advances, new merchandise and patents attained by opponents; challenges to patents; product efficacy or security issues leading to product recollects or regulatory motion; adjustments in conduct and spending patterns of purchasers of well being care services; adjustments to relevant legal guidelines and rules, together with world well being care reforms; and tendencies towards well being care price containment. An additional checklist and descriptions of those dangers, uncertainties and different elements will be present in Johnson & Johnson’s Annual Report on Type 10-Okay for the fiscal 12 months ended January 3, 2021, together with within the sections captioned “Cautionary Notice Relating to Ahead-Wanting Statements” and “Merchandise 1A. Threat Components,” and within the firm’s most not too long ago filed Quarterly Report on Type 10-Q, and the corporate’s subsequent filings with the Securities and Change Fee. Copies of those filings can be found on-line at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Not one of the Janssen Pharmaceutical Corporations nor Johnson & Johnson undertakes to replace any forward-looking assertion on account of new info or future occasions or developments.

References

1. Mease, P., et al. Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Assessment and Community Meta-Evaluation.  Offered at Maui Derm, January 24-26, 2022.
2. Meals and Drug Administration. TREMFYA® Prescribing Data. Horsham, PA. 2017. Out there at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf. Accessed January 2022.
3. Dias, S., et al. Proof Synthesis for Choice Making 2. Medical Choice Making, 2012:33(5), 607–617. https://doi.org/10.1177/0272989×12458724 
4. Dias, S., et al. Proof Synthesis for Choice Making 3. Medical Choice Making, 2013:33(5), 618–640. https://doi.org/10.1177/0272989×13485157
5. Dias, S., et al. Proof Synthesis for Choice Making 4. Medical Choice Making, 2013:33(5), 641–656. https://doi.org/10.1177/0272989×12455847
6. Mease, P., et al. Comparative effectiveness of guselkumab in psoriatic arthritis: outcomes from systematic literature evaluate and community meta-analysis. Rheumatology (Oxford). 2021 Might 14;60(5):2109-2121.
7. Coates L, et al. Efficacy and Security of Guselkumab in Sufferers With Lively Psoriatic Arthritis who’re Insufficient Responders to Tumor Necrosis Issue Inhibitors: Outcomes Via One Yr of a Section 3b, Randomized, Managed Research (COSMOS). Annals of the Rheumatic Illnesses. November 2021.
8. Deodhar, A., et al. Guselkumab in sufferers with energetic psoriatic arthritis who had been biologic-naive or had beforehand obtained TNFα inhibitor therapy (DISCOVER-1): a double-blind, randomised, placebo-controlled part 3 trial. The Lancet, 2020:395(10230), 1115–1125. https://doi.org/10.1016/s0140-6736(20)30265-8 
9. Mease, P., et al Guselkumab in biologic-naive sufferers with energetic psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled part 3 trial. The Lancet, 2020:395(10230), 1126–1136. https://doi.org/10.1016/s0140-6736(20)30263-4
10. McInnes, I., et al. Lengthy-term Efficacy and Security of Guselkumab, a Monoclonal Antibody Particular to the p19 Subunit of Interleukin-23, Via 2 Years: Outcomes from a Section 3, Randomized, Double-blind, Placebo-controlled Research Carried out in Biologic-naïve Sufferers with Lively Psoriatic Arthritis. Arthritis & Rheumatology, November 2021.
11. ClinicalTrials.gov. A Research of Guselkumab in Contributors With Lively Psoriatic Arthritis (APEX). Out there at: https://clinicaltrials.gov/ct2/show/NCT04882098. Accessed January 2022.
12. ClinicalTrials.gov. Guselkumab in Lively Psoriatic Arthritis Contributors With Insufficient Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE). Out there at: https://clinicaltrials.gov/ct2/show/NCT04936308. Accessed January 2022.
13. Thompson Jr., Dennis. How the Psoriasis Space and Severity Index Works. On a regular basis Well being. https://www.everydayhealth.com/psoriasis/living-with/how-the-pasi-index-works/ 
14. Sharp van der Heijde Rating | Rheumatology. Division of Drugs Division of Rheumatology. Accessed January 2022. http://rheumatology.usherbrooke.ca/?q=scoresharp 
15. Felson, D. T., & LaValley, M. P. The ACR20 and defining a threshold for response in rheumatic illnesses: an excessive amount of of a great factor. Arthritis Analysis & Remedy, 2014:16(1), 101. https://doi.org/10.1186/ar4428
16. Ruyssen-Witrand, A., et al. Efficacy and security of biologics in psoriatic arthritis: a scientific literature evaluate and community meta-analysis. RMD Open, 2020:6(1), e001117. https://doi.org/10.1136/rmdopen-2019-001117 
17. Kawalec, P., et al. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab therapy of psoriatic arthritis: a scientific evaluate and community meta-analysis. Rheumatology Worldwide, 2017:38(2), 189–201. https://doi.org/10.1007/s00296-017-3919-7 
18. McInnes, I., et al. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a community meta-analysis. Journal of Comparative Effectiveness Analysis, 2018:7(11), 1107–1123. https://doi.org/10.2217/cer-2018-0075 
19. Lu, C., et al. Comparative efficacy and security of focused DMARDs for energetic psoriatic arthritis throughout induction remedy: A scientific evaluate and community meta-analysis. Seminars in Arthritis and Rheumatism, 2019:49(3), 381–388. https://doi.org/10.1016/j.semarthrit.2019.06.001 
20. Belasco, J., & Wei, N. Psoriatic Arthritis: What’s Occurring on the Joint? Rheumatology and Remedy, 2019: 6(3), 305–315. https://doi.org/10.1007/s40744-019-0159-1  
21. Donvito T. CreakyJoints: What Is Enthesitis? The Painful Arthritis Symptom You Ought to Know About. Out there at: https://creakyjoints.org/symptoms/what-is-enthesitis/. Accessed October 2021.
22. Donvito T. CreakyJoints: What Is Dactylitis? The ‘Sausage Finger’ Swelling You Ought to Know About. Out there at: https://creakyjoints.org/symptoms/what-is-dactylitis/. Accessed October 2021.
23. Haddad A and Zisman D. Comorbidities in Sufferers with Psoriatic Arthritis. Rambam Maimonides Med J. 2017;8(1):e0004.
24. Nationwide Psoriasis Basis. About Psoriatic Arthritis. Out there at: https://www.psoriasis.org/about-psoriatic-arthritis/ Accessed January 2022.
25. Husted, J. A., et al. Incidence and correlates of fatigue in psoriatic arthritis. Annals of the Rheumatic Illnesses, 2008:68(10), 1553–1558. https://doi.org/10.1136/ard.2008.098202  
26. Cassell, S., & Kavanaugh, A. Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to therapy. Journal of Immune Primarily based Therapies and Vaccines. 2005;3:6. https://jibtherapies.biomedcentral.com/articles/10.1186/1476-8518-3-6  
27. Benson, J. M., et al. Discovery and mechanism of ustekinumab. MAbs, 2011:3(6), 535–545. https://doi.org/10.4161/mabs.3.6.17815 

Media Contact:
Bridget Kimmel
Cellular: (215) 688-6033

Investor Contact:
Raychel Kruper
Workplace: (732) 524-6164

SOURCE Janssen Pharmaceutical Corporations of Johnson & Johnson